Phase 3, Randomized, Double-Blind Trial of First-Line Pembrolizumab With or Without Lenvatinib in Metastatic NSCLC: LEAP-007 Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Mekhail, T.; Kim, S.; Kubota, K.; Del Riego, M. Gonzalez; Wu, L.; Samkari, A.; Fouad, T. M.; Yang, J. Chih-Hsin

authors

Publication Date

  • October 1, 2019

webpage

published in

category

keywords

  • Pembrolizumab
  • first-line
  • lenvatinib

start page

  • S405

end page

  • S405

volume

  • 14

issue

  • 10